Building Trusted AI at Scale Cities Startups & Digital Sovereignty – Keynote Kiran Mazumdar-Shaw

20 Feb 2026 12:00h - 13:00h

Session at a glance

Summary

Kiran Mazumdar-Shaw, Chairperson of Biocon Group, delivered a keynote address at India’s first Impact AI Summit, focusing on the critical need for India to develop biotech sovereignty embedded in artificial intelligence. She argued that while the 20th century was defined by the internet and the early 21st century by digital sovereignty, the coming decades will be shaped by the convergence of biological intelligence and artificial intelligence. Mazumdar-Shaw explained that biological intelligence, evolved over 3.8 billion years, represents the original intelligent machines with cells that sense, compute, and respond through intricate signaling networks while maintaining homeostasis through built-in guardrails.

She illustrated biological intelligence through examples like the immune system’s ability to memorize and respond to pathogens, and the Arctic tern’s remarkable 70,000-kilometer migration using navigational intelligence embedded in its DNA. The speaker emphasized that AI-powered biology is already compressing discovery timelines through protein structure prediction and generative drug design, but the next frontier involves reprogramming cells themselves to restore biological balance. She envisions moving from static drugs to programmable biology, including personalized CAR-T therapies, autoimmune interventions, and longevity treatments that work with biology’s natural regulatory circuits rather than overpowering them.

Mazumdar-Shaw stressed that India’s health security depends on combining “the code of life and the code of intelligence” through sovereign control over biological data, indigenous AI models, and translational platforms. She called for India to evolve from being the “pharmacy of the world” to becoming the “biotech platform of the world,” requiring a collaborative approach between government, academia, and industry. The transformation demands ethical, transparent AI systems that are globally interoperable yet rooted in public interest, positioning India as a leader in innovation that combines technological advancement with social purpose.

Keypoints

Major Discussion Points:

– Biotech Sovereignty as Strategic Imperative: The convergence of biological intelligence and artificial intelligence will define future decades, making biotech sovereignty embedded in AI a geopolitical necessity for nations, particularly India, to maintain control over healthcare, food security, and biosecurity.

– Biological Intelligence as the Original AI: Living systems have evolved over 3.8 billion years with sophisticated capabilities to sense, compute, respond, and maintain homeostasis through built-in guardrails – offering a model for how AI should operate with natural governance mechanisms.

– Paradigm Shift from Treatment to Reprogramming: Moving beyond traditional “one-size-fits-all” drugs toward programmable biology that can reprogram cancer cells, repair damaged tissue, and address aging by understanding and reinforcing biological regulatory circuits rather than overpowering them.

– India’s Evolution from “Pharmacy of the World” to “Biotech Platform of the World”: Transforming India’s role by embedding AI across the entire biotech value chain – from discovery and development to manufacturing and delivery – while maintaining sovereign control over biological data and AI models.

– Triple Helix Collaboration Model: Success requires coordinated efforts between government (investing in infrastructure and regulatory frameworks), academia (developing computational biology education), and industry (creating shared platforms and manufacturing clusters) to build ethical, globally interoperable yet locally controlled biotech systems.

Overall Purpose:

The discussion aims to present a strategic vision for India to achieve biotech sovereignty through AI integration, positioning the country as a global leader in AI-driven biotechnology while maintaining control over critical health security infrastructure and data.

Overall Tone:

The tone is consistently visionary, authoritative, and optimistic throughout. The speaker maintains an inspirational and forward-looking perspective, presenting complex scientific concepts with confidence while emphasizing both the tremendous opportunities and strategic imperatives facing India. The tone remains steady and purposeful from beginning to end, combining scientific expertise with geopolitical awareness.

Speakers

– Speaker 1: Role/Title: Not mentioned, Area of expertise: Not mentioned (appears to be an event moderator or host introducing the main speaker)

– Kiran Mazumdar-Shaw: Role/Title: Chairperson, Biocon Group, Area of expertise: Biotechnology, AI-biotech convergence, pharmaceutical industry, biotech sovereignty

Additional speakers:

None identified beyond those in the speakers names list.

Full session report

Kiran Mazumdar-Shaw, Chairperson of Biocon Group, delivered a comprehensive keynote address at India’s first-ever Impact AI Summit, presenting a strategic vision for India to achieve biotech sovereignty through the integration of artificial intelligence with biological systems. Taking off from where the previous panel discussed sovereignty, her presentation argued that the convergence of biological intelligence and artificial intelligence represents the defining technological frontier of the coming decades, positioning it as a strategic imperative for national security and economic resilience.

Historical Context and the New Frontier

Mazumdar-Shaw began by establishing historical context, noting that the 20th century was defined by the Internet and the early 21st century by digital sovereignty. She argued that we now stand at the threshold of a new era where biotech sovereignty embedded in AI will define the future. This represents not merely a commercial opportunity but a fundamental shift in how nations must think about strategic autonomy and health security.

The Foundation: Biological Intelligence as the Original AI

Mazumdar-Shaw’s central thesis rests on a fundamental reframing of intelligence itself. She argued that living systems represent “the original intelligent machines,” having evolved sophisticated computational capabilities over 3.8 billion years. This biological intelligence operates through intricate cellular networks that sense, compute, and respond to multimodal signals whilst maintaining homeostasis—what she defined as “health equilibrium”—through inbuilt biological guardrails. Disease arises when these guardrails fail.

To illustrate this concept, she provided compelling examples of biological intelligence in action. The immune system demonstrates remarkable information processing capabilities, responding to pathogens through immunological mechanisms like cytokines, antibodies, and killer T cells, whilst simultaneously creating memory through T and B cells that can rapidly retrieve and act upon stored pathogen information years later. Perhaps even more striking is the Arctic tern’s extraordinary 70,000-kilometre migration between the Arctic and Antarctic, accomplished by a tennis ball-sized bird with no prior knowledge and no older bird to guide it, relying entirely on navigational intelligence embedded within its DNA.

These biological systems operate with extraordinary energy efficiency that current AI cannot match. Whilst artificial intelligence requires gigawatts of power through massive data centres, biological intelligence utilises distributed processing that “takes sips of energy when it needs to use it.” The human brain, described as “the biggest supercomputer known to man,” exemplifies this efficiency, processing vast amounts of information whilst consuming minimal energy compared to artificial systems that learn from data to optimise decisions at machine scale.

The Paradigm Shift: From Treatment to Programmable Biology

Building upon this foundation, Mazumdar-Shaw outlined a transformative shift from traditional pharmaceutical approaches to what she termed “programmable biology.” Rather than relying on static, one-size-fits-all drugs that often work against biological systems, the future lies in understanding and working with biological intelligence to reprogram cellular functions at their source through gene regulation, gene regulatory circuits, and immune memory.

This approach promises revolutionary therapeutic possibilities: reprogramming cancer cells into non-malignant cells, repairing previously irreparable bone tissue damage, and developing personalised CAR-T therapies that eliminate tumours with precision. In autoimmune diseases, rather than broadly suppressing immunity, future interventions could recalibrate immune tolerance whilst preserving protective functions. As the previous speaker discussed, understanding how senescence is modulated and cellular repair mechanisms function could enable interventions that delay biological aging and extend healthy lifespan significantly.

Crucially, these approaches seek not to overpower biological systems but to reinforce their inherent regulatory circuits. By understanding how biological intelligence maintains homeostasis through feedback loops and control mechanisms, AI can map these regulatory circuits at scale, enabling targeted interventions that preserve rather than disrupt biological balance.

Strategic Imperative: India’s Biotech Sovereignty

Mazumdar-Shaw positioned this technological convergence within a broader geopolitical context, arguing that nations commanding the intersection of biological and artificial intelligence will define the future across multiple domains including healthcare, food security, education, biomanufacturing, sustainability, and biosecurity. For India, this represents not merely an economic opportunity but a matter of national security and strategic autonomy, particularly for preparedness against pandemics, antimicrobial resistance, and emerging new bio-threats.

The speaker emphasised that if foundational AI models for drug discovery, genomics, cellular engineering, and clinical decision-making remain under offshore control, India risks strategic dependence in the most critical domain of national resilience: human health. Therefore, biotech sovereignty must encompass sovereign control over trusted biological data, indigenous AI models, computing infrastructure, and complete translational platforms spanning from discovery and development through to manufacturing and delivery.

This sovereignty framework positions India to evolve from being “the pharmacy of the world” to becoming “the biotech platform of the world,” offering AI-native discovery engines, programmable therapy platforms, and scalable biomanufacturing capabilities as global public goods.

Implementation Framework: AI Integration and Compressed Timelines

The practical realisation of this vision requires systematic AI integration across the entire biotechnology value chain. In the discovery phase, India must develop foundation models for proteins, RNA, cellular circuits, and systems biology. AI promises to compress discovery timelines and reduce development risk through in silico trials, digital twins of biological systems, and AI-driven trial design that can significantly de-risk pipeline development.

Manufacturing represents another critical area where AI can enable smart biomanufacturing through yield optimisation and quality-by-design approaches. However, Mazumdar-Shaw identified a crucial bottleneck: regulatory frameworks must evolve to match the pace of technological advancement. She advocated for science-first, tech-enabled regulatory pathways that integrate real-world evidence through AI validation, warning that if regulatory speed fails to keep pace with compressed discovery and development timelines, significant opportunities will be lost.

Collaborative Architecture: The Triple Helix Model and Beyond

Recognising that such transformation cannot be achieved by industry alone, Mazumdar-Shaw outlined a “triple helix” collaboration model involving government, academia, and industry, each with specific roles and responsibilities. Government must invest in sovereign AI bio-infrastructure, trusted data architectures, regulatory sandboxes, and mission-mode programmes in cell and gene therapy, immuno-oncology, and longevity science.

Academia’s role involves mainstreaming computational biology, neurosymbolic AI, and AI-first life sciences education to build a new cadre of translational scientists capable of working at the intersection of biology and artificial intelligence. Industry must co-create shared platforms, translational pipelines, and globally benchmarked biomanufacturing clusters that convert scientific discoveries into scalable solutions.

Additionally, capital markets must evolve to support the unique requirements of biotech innovation, which typically involves long development cycles, high risk, and substantial research and development investment. The development of patient capital mechanisms is essential for supporting deep science research, particularly in startup environments where such innovation often originates.

Ethical Leadership and Global Interoperability

Addressing potential concerns about technological nationalism, Mazumdar-Shaw emphasised that “sovereignty is not isolation.” She advocated for India to build ethical, transparent, energy-efficient, and bias-aware AI systems for biology that remain globally interoperable whilst being rooted in public interest. This approach could position India as offering a distinctive model of innovation that combines technological leadership with social purpose.

Conclusion: Mastering the Languages of Life and Machines

Mazumdar-Shaw concluded by framing biotech sovereignty embedded in AI not as a sectoral ambition but as a foundation for health security, strategic autonomy, and economic resilience. She argued that “those who master the language of life augmented by the language of machines will shape the future of humanity,” positioning India as uniquely positioned to lead this transformation given its scientific capabilities, AI and life sciences talent, scale, and values.

The urgency of her message lies in the recognition that the foundations for this biotech-AI convergence must be built today to secure tomorrow’s strategic positioning. As AI compresses discovery timelines and reduces development risk, the nations and organisations that establish sovereign capabilities in this domain will define the future of human health and biological innovation.

Session transcript

Speaker 1

Ladies and gentlemen, please put your hands together to welcome Ms. Kiran Mazumdar -Shaw, Chairperson, Biocon Group.

Kiran Mazumdar-Shaw:

Good afternoon, and let me say how delighted I am to be a part of this wonderful summit, the Impact AI Summit that India… is launching and hosting for the first time, which I think heralds a big signal that we are part of the AI journey that the world is on. I’ve basically taken off from where the last panel talked about sovereignty, and I thought I should talk about why India must build biotech sovereignty that is embedded in AI. And let me start with this first slide that basically says that if the 20th century was defined by the Internet and the early 21st century by digital sovereignty, which was all about data being the new oil and the new fuel, the coming decades, I believe, will be… …be shaped by… biotech sovereignty that is embedded in AI.

I believe that nations that command the convergence of biology and AI, or what I like to call the convergence of biological intelligence and artificial intelligence, will define the future of healthcare, food security, education, biomanufacturing, sustainability, biosecurity, and much more. For India, this is not merely a cutting -edge opportunity. It is a strategic and geopolitical imperative. Now, let me really touch upon what I mean by biological intelligence. Living systems are the original intelligent machines. And why do I say this? Because biological intelligence has evolved and has been built over 3 .8 billion years. It is different in the way it learns, memorizes, builds and processes information from multimodal signals and circuits. Cells sense, they compute and they respond through intricate signaling networks.

They also then interface with gene regulation and gene regulatory circuits and immune memory. These systems operate within inbuilt biological guardrails, which form a network of cells that are connected to each other. They focus on feedback loops and control mechanisms that maintain what we refer to as homeostasis. or health equilibrium. Disease arises when these guardrails fail. So when we talk about ethics, when we talk about governance, living systems have an inbuilt sense of guardrails and governance, which is about keeping you healthy, which is about homeostasis, which is a wonderful way of making sure that it compensates, it repairs and makes sure that you can still live in a health as healthier way as possible. And to illustrate this, let’s look at the way our immune system responds to pathogens.

The immune system responds through immunological ammunition like cytokines, antibodies and killer T cells. It also memorizes the identity of the pathogen in memory T cells and B cells. And years later, when the pathogen reinvades, the memory cells rapidly retrieve this information and translate it into instant action. This is the marvels of biology in the way it receives information, processes information, stores information, retrieves information and acts. And the inference of all this information is done at speed and with energy efficiency that we can’t even imagine. We don’t need those gigawatts of data centers. We have distributed data centers that take sips of energy when it needs to use it. Our brain, which is the biggest supercomputer known to man, does this.

So efficiently that we need to understand how biology works. Another great thought -provoking example of biological intelligence is the migration of the Arctic tern. This little bird, that is the size of a tennis ball, undertakes a 70 ,000 -kilometer journey between the Arctic, the Antarctic and back with no prior knowledge, with no older bird to guide it, and yet it does it with astonishing precision and speed. How does it do it? This is about navigational intelligence embedded in its DNA. AI, by contrast, learns from data to optimize decisions at machine scale. So therefore, the true… The true inflection point lies at their intersection. AI -powered biology… from protein structure prediction and generative drug design to digital twins of cells and organs.

AI is compressing discovery timelines and reducing development risk. And therefore, I believe that the next frontier is even more profound. The reprogramming of cells themselves to restore biological balance. But for this, we need to understand how biological intelligence operates. Imagine reprogramming cancer cells into non -malignant cells. Imagine repairing bone tissue that is damaged and irreparable. Biological intelligence is built on an intricate network of cell signaling, gene regulation and immune memory that works symbiotically, as I mentioned, to maintain homogenization. And so, we need to understand how biological intelligence operates. And so, we need to understand how biological intelligence operates. And so, we need to understand how biological intelligence operates. now if we now come to what i’ve just spoken about which is reprogramming and re -engineering we are moving from static one -size -fits -all drugs to programmable biology which is the new frontier we need to learn how biology learns stores data retrieves and processes data in such an agile and energy efficient way once we understand the computational models of living systems we can use ai to accelerate with predictive precision the most advanced present -day therapies today we are all excited about personalized carti therapies that basically eliminate tumors with precision autoimmune disease interventions that are used to eliminate tumors with precision that recalibrate immune tolerance rather than broadly suppressing immunity And then the most exciting part of longevity and health span.

These are areas where we must understand how senescence is modulated, metabolic pathways of aging are created and cellular repair mechanisms to delay biological aging and restore tissue resilience happens. If we understand all this, as the last speaker said, we may be able to live for another 50 years and more. Flucially, these approaches seek not to overpower biology but to reinforce its inbuilt guardrails or regulatory circuits which focus on repair, feedback control and immune surveillance. AI can map these regulatory circuits at scale, enabling target interventions that preserve homeostasis. That is the excitement of new science led by AI, new biology led by AI. This represents a paradigm shift from managing disease to re -engineering biological systems to sustain equilibrium.

So, India’s future health security will depend on how optimally we combine the code of life and the code of intelligence. If foundational AI models for drug discovery, genomics, cellular engineering and clinical decision making are owned offshore, India risks strategic dependence in the market. This is the most critical domain of national resilience, which is human health. Biotech sovereignty embedded in AI must therefore mean sovereign control over trusted biological data. indigenous AI models, computing infrastructure, and translational platforms from discovery and development to manufacturing and delivery. This is essential not only for economic competitiveness, but also for preparedness against pandemics, antimicrobial resistance, and emerging new bio -threats. Now, I really believe this is a very important aspect of what AI can do for biotech and the economy.

AI alone will not create economic opportunities, but the delivery of AI in our field through manufacturing and products will do that. India’s global role must evolve from being the pharmacy of the world, to becoming the biotech platform of the world, a nation that offers AI -native discovery engines programmable therapy platforms and scalable biomanufacturing as global public goods. And this requires embedding AI across the biotech value chain. When it comes to discovery, we need to develop foundation models for proteins, RNA, cellular circuits and systems biology. When it comes to development, I think there are huge opportunities to develop in silico trials, digital twins and AI driven trial design to really de -risk the success of pipelines and probability of success.

When it comes to manufacturing, smart biomanufacturing using AI for yield optimization and most importantly, quality by design is going to be a great opportunity for all of us. Now, when it comes to the biotech value chain, we need to develop a system of biomanufacturing and also a system of biotech regulation. It has to be a science -first approach, tech -enabled regulatory pathways, integrating real -world evidence through AI validation. I think that’s going to be a huge opportunity which we must do right now. What is important is for regulations to keep up with technology. If we compress timelines of discovery and development to a fraction of what happens today, and if regulatory speed does not keep up with it, then we miss out on a huge lost opportunity.

So working in tandem, working in synchronization is the need of the hour. This transformation cannot be driven by industry alone. It demands a triple helix of government, academia and industry. Government, academia and industry. Government must invest in sovereign AI bio -infrastructure. trusted data architectures, regulatory sandboxes, and mission mode programs in cell and gene therapy, immuno -oncology, and longevity science. Academia must mainstream computational biology, neurosymbolic AI, and AI -first life sciences education to build a new cadre of translational scientists. Industry must co -create shared platforms, translational pipelines, and globally benchmarked biomanufacturing clusters that convert science into scale. Capital markets must also evolve to support long -cycle, high -risk biotech innovation that is so rampant in startups in our country.

Deep science requires a lot of research and development. It requires patient capital. But the societal and economic returns from reduced disease burden to global platform leadership are exponential. Now coming to ethics, trust and global leadership. Sovereignty is not isolation. India must build ethical, transparent, energy efficient and bias aware AI systems for biology that are globally interoperable yet rooted in public interest. And I think this is the unique model India can create. By embedding principles of equity, affordability and access into AI driven. AI. AI driven biotech, India can offer the world a new model of innovation combining technological leadership with social purpose. For India, biotech sovereignty embedded in AI is not a sectoral ambition. It is a foundation of health security, strategic autonomy and economic resilience.

Those who master the language of life augmented by the language of machines will shape the future of humanity. India has the science, the AI and life sciences talent, the scale and the values to lead provided it builds the sovereign platforms of tomorrow today. Thank you.

Kiran Mazumdar-Shaw

Speech speed

106 words per minute

Speech length

Ethics, trust, and global leadership in AI‑biotech

Topics

Human rights and the ethical dimensions of the information society | Artificial intelligence | Data governance

Speaker 1

Speech speed

118 words per minute

Speech length

17 words

Speech time

8 seconds

Highlighting biotech leadership in AI-driven health initiatives

Explanation

By publicly welcoming Ms. Kiran Mazumdar‑Shaw, the speaker underscores the pivotal role of biotech leaders in shaping the convergence of biology and artificial intelligence, signaling the importance of such expertise for national health security and innovation.

Evidence

“Ladies and gentlemen, please put your hands together to welcome Ms. Kiran Mazumdar‑Shaw, Chairperson, Biocon Group.” [1].

Major discussion point

Recognition of biotech leadership in AI‑enabled health transformation

Topics

Social and economic development | Artificial intelligence

Agreements

Agreement points

AI integration across biotechnology value chain is essential for India’s strategic positioning

Speakers

– Kiran Mazumdar-Shaw

Arguments

Nations commanding the convergence of biology and AI will define the future of healthcare, food security, and sustainability – Biotech sovereignty is a strategic and geopolitical imperative for India

India must evolve from being the pharmacy of the world to becoming the biotech platform of the world offering AI-native discovery engines as global public goods

AI must be embedded across discovery (foundation models for proteins and cellular circuits), development (in silico trials and digital twins), and manufacturing (smart biomanufacturing with yield optimization)

Summary

There is clear consensus that AI integration throughout the biotechnology sector is crucial for India’s transformation from a pharmaceutical manufacturer to a comprehensive biotech platform, representing a strategic imperative for national competitiveness

Topics

Artificial intelligence | Social and economic development | The enabling environment for digital development

Multi-stakeholder collaboration is necessary for biotechnology transformation

Speakers

– Kiran Mazumdar-Shaw

Arguments

Transformation requires a triple helix of government, academia, and industry working together with specific roles for each sector

Capital markets must evolve to support long-cycle, high-risk biotech innovation with patient capital for deep science research and development

Summary

There is agreement that successful biotechnology development requires coordinated efforts from government, academia, industry, and financial markets, each playing distinct but complementary roles

Topics

The enabling environment for digital development | Capacity development | Financial mechanisms

Ethical and responsible AI development in biotechnology is paramount

Speakers

– Kiran Mazumdar-Shaw

Arguments

India must build ethical, transparent, energy-efficient and bias-aware AI systems for biology that are globally interoperable yet rooted in public interest

By embedding principles of equity, affordability and access into AI-driven biotech, India can offer the world a new model combining technological leadership with social purpose

These approaches seek to reinforce biology’s inbuilt guardrails rather than overpower them, enabling interventions that preserve homeostasis

Summary

There is consensus on the importance of developing AI systems for biotechnology that are ethical, transparent, and socially responsible while maintaining global interoperability and focusing on public benefit

Topics

Human rights and the ethical dimensions of the information society | Artificial intelligence | Data governance

Similar viewpoints

Biological intelligence serves as both inspiration and foundation for developing more efficient AI systems, with the convergence of biological and artificial intelligence representing the most significant technological opportunity

Speakers

– Kiran Mazumdar-Shaw

Arguments

Living systems are the original intelligent machines, evolved over 3.8 billion years with inbuilt biological guardrails that maintain homeostasis

Biological systems operate with energy efficiency that surpasses current AI systems, using distributed data centers that take sips of energy when needed

The true inflection point lies at the intersection of biological and artificial intelligence, enabling AI-powered biology from protein structure prediction to digital twins of cells

Topics

Artificial intelligence | Environmental impacts

The future of medicine lies in personalized, programmable biological interventions that can fundamentally alter disease processes rather than simply managing symptoms

Speakers

– Kiran Mazumdar-Shaw

Arguments

The future involves moving from static one-size-fits-all drugs to programmable biology that can reprogram cancer cells into non-malignant cells and repair irreparable tissue damage

Advanced therapies like personalized CAR-T therapies, autoimmune interventions, and longevity treatments represent the new frontier of medicine

Topics

Social and economic development | Artificial intelligence

Regulatory systems must evolve to match the accelerated pace of AI-driven biotechnology development to avoid missing transformative opportunities

– Kiran Mazumdar-Shaw

Arguments

India must build ethical, transparent, energy-efficient and bias-aware AI systems for biology that are globally interoperable yet rooted in public interest

Explanation

The consensus on balancing national sovereignty with global interoperability is unexpected as these concepts are often viewed as conflicting, but here they are presented as complementary aspects of responsible biotechnology development

Topics

Human rights and the ethical dimensions of the information society | Artificial intelligence | Data governance

Overall assessment

Summary

The discussion demonstrates strong internal consistency around the strategic importance of AI-biotechnology convergence, multi-stakeholder collaboration, ethical development, and the need for regulatory evolution. Key areas of agreement include India’s transformation from pharmaceutical manufacturer to biotech platform, the necessity of coordinated government-academia-industry collaboration, and the importance of ethical, globally interoperable AI systems.

Consensus level

High level of consensus within the single speaker’s comprehensive vision, with implications for India’s strategic positioning in global biotechnology leadership, the need for coordinated policy frameworks, and the potential for creating a new model of socially responsible technological development that could influence global standards

Differences

Different viewpoints

Unexpected differences

Overall assessment

Summary

No disagreements identified in this transcript

Disagreement level

This transcript contains only a single keynote presentation by Kiran Mazumdar-Shaw with a brief introduction by Speaker 1. There are no opposing viewpoints, debates, or disagreements present. The format is a monologue presentation rather than a discussion or debate between multiple speakers with differing perspectives. All arguments presented are from one speaker’s unified perspective on biotech sovereignty and AI integration.

Partial agreements

Similar viewpoints

Biological intelligence serves as both inspiration and foundation for developing more efficient AI systems, with the convergence of biological and artificial intelligence representing the most significant technological opportunity

Speakers

– Kiran Mazumdar-Shaw

Arguments

Living systems are the original intelligent machines, evolved over 3.8 billion years with inbuilt biological guardrails that maintain homeostasis

Biological systems operate with energy efficiency that surpasses current AI systems, using distributed data centers that take sips of energy when needed

The true inflection point lies at the intersection of biological and artificial intelligence, enabling AI-powered biology from protein structure prediction to digital twins of cells

Topics

Artificial intelligence | Environmental impacts

The future of medicine lies in personalized, programmable biological interventions that can fundamentally alter disease processes rather than simply managing symptoms

Speakers

– Kiran Mazumdar-Shaw

Arguments

The future involves moving from static one-size-fits-all drugs to programmable biology that can reprogram cancer cells into non-malignant cells and repair irreparable tissue damage

Advanced therapies like personalized CAR-T therapies, autoimmune interventions, and longevity treatments represent the new frontier of medicine

Topics

Social and economic development | Artificial intelligence

Regulatory systems must evolve to match the accelerated pace of AI-driven biotechnology development to avoid missing transformative opportunities

Speakers

– Kiran Mazumdar-Shaw

Arguments

Regulatory frameworks must adopt a science-first, tech-enabled approach with AI validation to keep pace with compressed discovery and development timelines

Topics

The enabling environment for digital development | Artificial intelligence

Takeaways

Key takeaways

The coming decades will be shaped by biotech sovereignty embedded in AI, where nations commanding the convergence of biological and artificial intelligence will define the future of healthcare, food security, and sustainability

Biological intelligence, evolved over 3.8 billion years, operates with superior energy efficiency and built-in guardrails compared to current AI systems, offering a model for more efficient computing

The future of medicine lies in programmable biology – moving from static drugs to reprogramming cells themselves, such as converting cancer cells to non-malignant cells and repairing irreparable tissue damage

India must transition from being ‘the pharmacy of the world’ to becoming ‘the biotech platform of the world’ by developing AI-native discovery engines and programmable therapy platforms

AI must be embedded across the entire biotech value chain – from discovery (foundation models for proteins) to development (digital twins, in silico trials) to manufacturing (smart biomanufacturing)

Regulatory frameworks must evolve to keep pace with AI-compressed discovery timelines through science-first, tech-enabled approaches

Success requires a ‘triple helix’ collaboration between government, academia, and industry, with each sector playing specific roles in building sovereign AI bio-infrastructure

India can lead globally by creating ethical, transparent AI systems for biology that combine technological leadership with social purpose, embedding principles of equity, affordability, and access

Resolutions and action items

Government must invest in sovereign AI bio-infrastructure, trusted data architectures, regulatory sandboxes, and mission mode programs in cell and gene therapy, immuno-oncology, and longevity science

Academia must mainstream computational biology, neurosymbolic AI, and AI-first life sciences education to build a new cadre of translational scientists

Industry must co-create shared platforms, translational pipelines, and globally benchmarked biomanufacturing clusters that convert science into scale

Capital markets must evolve to support long-cycle, high-risk biotech innovation with patient capital for deep science research and development

Build sovereign platforms for biotech sovereignty embedded in AI today to secure India’s future health security and strategic autonomy

Unresolved issues

Specific mechanisms for how regulatory speed can be synchronized with compressed AI-driven discovery and development timelines

Detailed implementation strategies for building the proposed triple helix collaboration between government, academia, and industry

Concrete steps for developing the required patient capital ecosystem for long-cycle biotech innovation

Specific technical approaches for understanding and mapping biological intelligence computational models

Practical methods for ensuring global interoperability while maintaining sovereign control over biological data and AI models

Suggested compromises

Balancing sovereignty with global collaboration – building systems that are ‘globally interoperable yet rooted in public interest’ rather than pursuing complete isolation

This reconciles the tension between national sovereignty and global collaboration, proposing a third way that combines strategic autonomy with ethical leadership. It positions India as potentially offering a more socially conscious model of technological development.

Impact

This comment provides a philosophical and ethical framework for the entire biotech sovereignty agenda, showing how India could differentiate itself globally not just through technology but through values-driven innovation.

Overall assessment

Explanation

Represents the ultimate goal of programmable biology – not just treating disease but fundamentally reprogramming biological systems to restore health and function.

Disclaimer: This is not an official session record. DiploAI generates these resources from audiovisual recordings, and they are presented as-is, including potential errors. Due to logistical challenges, such as discrepancies in audio/video or transcripts, names may be misspelled. We strive for accuracy to the best of our ability.